FDG-PET in Relapsed/Refractory Hodgkin Lymphoma: a practical approach.

According to Lugano response criteria, FDG-PET is mandatory to define metabolic response to frontline therapy and moreover it is important in the definition of non-responders or refractory disease patients. Refractory disease is reported in about 15% of patients, with some variations based on the choice of first line chemotherapy and particularly in advanced stages up to 40% eventually relapse within 3 years. Key Messagges: The aim of this review is to highlight a practical way to use FDG-PET in the subset of HL, with some notes of its use in first line patients, and particularly centred on relapsed or refractory setting with a final focus of the evaluation of response by FDG-PET in the new treatment era of immunocheckpoint inhibitors (CPI).